Company Overview of Eagle Pharmaceuticals Inc.
Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban to treat heparin-induced thrombocytopenia; and Ryanodex injectable suspension for the treatment of malignant hyperthermia. It develops EP-3101, a bendamustine ready to dilute (RTD) liquid and EP-3102, a bendamustine short infusion time RTD liquid for the treatment of chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma;; and EP-4104, a dantrolene for the treatment of exertional heat stroke. The company also develops EP-5101 (pemetrexed) as RTD liquid, whi...
50 Tice Boulevard
Woodcliff Lake, NJ 07677
Founded in 2007
Key Executives for Eagle Pharmaceuticals Inc.
Chief Executive Officer, President and Director
Total Annual Compensation: $449.6K
Chief Financial Officer
Total Annual Compensation: $265.9K
Chief Medical Officer and Head of Research & Development
Total Annual Compensation: $303.8K
Chief Scientific Officer
Total Annual Compensation: $352.4K
Compensation as of Fiscal Year 2014.
Eagle Pharmaceuticals Inc. Key Developments
Eagle Pharmaceuticals Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 04:30 PM
May 21 15
Eagle Pharmaceuticals Inc. Presents at Jefferies 2015 Global Healthcare Conference, Jun-03-2015 04:30 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: David E. Riggs, Chief Financial Officer, Scott L. Tarriff, Chief Executive Officer, President and Director.
Eagle Pharmaceuticals Inc. Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-09-2015 12:50 PM
May 21 15
Eagle Pharmaceuticals Inc. Presents at William Blair’s 35th Annual Growth Stock Conference, Jun-09-2015 12:50 PM. Venue: Four Seasons Hotel, Chicago, Illinois, United States. Speakers: David E. Riggs, Chief Financial Officer, Scott L. Tarriff, Chief Executive Officer, President and Director.
Eagle Pharmaceuticals, Inc. Submits New Drug Application for Ready-To-Use Bivalirudin to U.S. Food and Drug Administration
May 20 15
Eagle Pharmaceuticals Inc. has submitted a 505(b)(2) New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for its novel ready-to-use bivalirudin product (RTU bivalirudin). This product is a stable liquid intravenous formulation of bivalirudin, the same active ingredient as in The Medicine company’s Angiomax (bivalirudin). U.S. sales of Angiomax were approximately $600 million for the twelve months ended December 31, 2014. This 505(b)(2) NDA requests FDA approval of Eagle’s RTU bivalirudin product for the treatment of patients: 1) undergoing percutaneous coronary intervention (PCI) with use of glycoprotein IIb/IIIa inhibitor, 2) undergoing PCI with, or at risk of, heparin-induced thrombocytopenia and thrombosis syndrome, and/or 3) with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA). RTU bivalirudin is intended for use with aspirin.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|